Skip to main content
Top
Published in: BMC Nephrology 1/2017

Open Access 01-12-2017 | Research article

Hyperuricemia after orthotopic liver transplantation: divergent associations with progression of renal disease, incident end-stage renal disease, and mortality

Authors: Joseph C. Longenecker, Sana Waheed, Ghassan Bandak, Christine A. Murakami, Blaithin A. McMahon, Allan C. Gelber, Mohamed G. Atta

Published in: BMC Nephrology | Issue 1/2017

Login to get access

Abstract

Background

Although hyperuricemia is common after orthotopic liver transplantation (OLT), its relationship to mortality, progressive kidney disease, or the development of end stage renal disease (ESRD) is not well-described.

Methods

Data from 304 patients undergoing OLT between 1996 and 2010 were used to assess the association of mean serum uric acid (UA) level in the 3-months post-OLT with mortality, doubling of creatinine, and ESRD incidence. Post-OLT survival to event outcomes according to UA level and eGFR was assessed using the Kaplan Meier method and multivariate Cox proportional hazards models.

Results

Mean UA level among the 204 patients with an eGFR level ≥60 ml/min/1.73 m2 was 6.4 mg/dl compared to 7.9 mg/dl among the 100 patients with eGFR <60 (p < 0.0001). During a median of 4.6 years of follow-up, mortality rate, doubling of creatinine, and ESRD incidence were 48.9, 278.2, and 20.7 per 1000 person-years, respectively. In the first 5 years of follow-up, elevated UA was associated with mortality (Hazard Ratio, HR = 1.7; p = 0.045). However, among those with eGFR ≥ 60, UA level did not predict mortality (HR = 1.0; p = 0.95), and among those with eGFR < 60, elevated UA was a strong predictor of mortality (HR = 3.7[1.1, 12.0]; p = 0.03). UA was not associated with ESRD, but was associated with doubling of creatinine among diabetics (HR = 2.2[1.1, 4.3]; p = 0.025).

Conclusion

In this post-OLT cohort, hyperuricemia independently predicted mortality, particularly among patients with eGFR < 60, and predicted doubling of creatinine among diabetics.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lin HY, Rocher LL, McQuillan MA, Palella TD, Fox IH. Hyperuricemia and gout in cyclosporin A-treated renal transplant recipients. Adv Exp Med Biol. 1989;253A:289–92.CrossRefPubMed Lin HY, Rocher LL, McQuillan MA, Palella TD, Fox IH. Hyperuricemia and gout in cyclosporin A-treated renal transplant recipients. Adv Exp Med Biol. 1989;253A:289–92.CrossRefPubMed
2.
go back to reference Burack DA, Griffith BP, Thompson ME, Kahl LE. Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med. 1992;92(2):141–6.CrossRefPubMed Burack DA, Griffith BP, Thompson ME, Kahl LE. Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med. 1992;92(2):141–6.CrossRefPubMed
3.
go back to reference Neal DA, Tom BD, Gimson AE, Gibbs P, Alexander GJ. Hyperuricemia, gout, and renal function after liver transplantation. Transplantation. 2001;72(10):1689–91.CrossRefPubMed Neal DA, Tom BD, Gimson AE, Gibbs P, Alexander GJ. Hyperuricemia, gout, and renal function after liver transplantation. Transplantation. 2001;72(10):1689–91.CrossRefPubMed
5.
go back to reference Longenecker JC, Estrella MM, Segev DL, Atta MG. Patterns of Kidney Function Before and After Orthotopic Liver Transplant: Associations With Length of Hospital Stay, Progression to End-Stage Renal Disease, and Mortality. Transplantation. 2015;99(12):2556–64.CrossRefPubMed Longenecker JC, Estrella MM, Segev DL, Atta MG. Patterns of Kidney Function Before and After Orthotopic Liver Transplant: Associations With Length of Hospital Stay, Progression to End-Stage Renal Disease, and Mortality. Transplantation. 2015;99(12):2556–64.CrossRefPubMed
6.
go back to reference Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404–10.CrossRefPubMed Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404–10.CrossRefPubMed
7.
go back to reference Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology. 1999;10(4):391–7.CrossRefPubMed Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology. 1999;10(4):391–7.CrossRefPubMed
8.
go back to reference Miyaoka T, Mochizuki T, Takei T, Tsuchiya K, Nitta K. Serum uric acid levels and long-term outcomes in chronic kidney disease. Heart Vessel. 2014;29(4):504–12.CrossRef Miyaoka T, Mochizuki T, Takei T, Tsuchiya K, Nitta K. Serum uric acid levels and long-term outcomes in chronic kidney disease. Heart Vessel. 2014;29(4):504–12.CrossRef
9.
go back to reference Iseki K, Iseki C, Kinjo K. Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa, Japan. Hypertens Res. 2013;36(7):650–4.CrossRefPubMed Iseki K, Iseki C, Kinjo K. Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa, Japan. Hypertens Res. 2013;36(7):650–4.CrossRefPubMed
10.
go back to reference Nacak H, van Diepen M, Qureshi AR, Carrero JJ, Stijnen T, Dekker FW, Evans M. Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease. Nephrol Dial Transplant. 2015;30(12):2039–45.CrossRefPubMedPubMedCentral Nacak H, van Diepen M, Qureshi AR, Carrero JJ, Stijnen T, Dekker FW, Evans M. Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease. Nephrol Dial Transplant. 2015;30(12):2039–45.CrossRefPubMedPubMedCentral
11.
go back to reference Moreno JM, Cuervas-Mons V, Rubio E, Pons F, de Herreros TA, Turrion VS, Millan I. Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc. 2003;35(5):1907–8.CrossRefPubMed Moreno JM, Cuervas-Mons V, Rubio E, Pons F, de Herreros TA, Turrion VS, Millan I. Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc. 2003;35(5):1907–8.CrossRefPubMed
13.
go back to reference Johnson RJ, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013;28(9):2221–8.CrossRefPubMedPubMedCentral Johnson RJ, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013;28(9):2221–8.CrossRefPubMedPubMedCentral
14.
go back to reference Dahle DO, Jenssen T, Holdaas H, Leivestad T, Vardal M, Mjoen G, Reisaeter AV, Toft I, Hartmann A. Uric acid has a J-shaped association with cardiovascular and all-cause mortality in kidney transplant recipients. Clin Transpl. 2014;28(1):134–40.CrossRef Dahle DO, Jenssen T, Holdaas H, Leivestad T, Vardal M, Mjoen G, Reisaeter AV, Toft I, Hartmann A. Uric acid has a J-shaped association with cardiovascular and all-cause mortality in kidney transplant recipients. Clin Transpl. 2014;28(1):134–40.CrossRef
15.
go back to reference Pagonas N, Kor S, Seibert FS, Giese A, Zidek W, Reinke P, Babel N, Bauer F, Westhoff TH. Effects of Treatment of Asymptomatic Hyperuricemia on Graft Survival and Mortality in Kidney Transplant Recipients. Ann Transplant. 2016;21:350–9.CrossRefPubMed Pagonas N, Kor S, Seibert FS, Giese A, Zidek W, Reinke P, Babel N, Bauer F, Westhoff TH. Effects of Treatment of Asymptomatic Hyperuricemia on Graft Survival and Mortality in Kidney Transplant Recipients. Ann Transplant. 2016;21:350–9.CrossRefPubMed
16.
go back to reference Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91–6.CrossRefPubMed Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91–6.CrossRefPubMed
17.
go back to reference Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentral Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentral
18.
go back to reference National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.
19.
go back to reference Arora S, Aukrust P, Ueland T, Broch K, Simonsen S, Gude E, Fiane AE, Geiran O, Wergeland R, Andreassen AK, et al. Elevated serum uric acid levels following heart transplantation predict all-cause and cardiac mortality. Eur J Heart Fail. 2009;11(10):1005–13.CrossRefPubMed Arora S, Aukrust P, Ueland T, Broch K, Simonsen S, Gude E, Fiane AE, Geiran O, Wergeland R, Andreassen AK, et al. Elevated serum uric acid levels following heart transplantation predict all-cause and cardiac mortality. Eur J Heart Fail. 2009;11(10):1005–13.CrossRefPubMed
20.
go back to reference Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010;62(2):170–80. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010;62(2):170–80.
21.
go back to reference Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131(1):7–13.CrossRefPubMed Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131(1):7–13.CrossRefPubMed
22.
go back to reference Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13(12):2888–97.CrossRefPubMed Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13(12):2888–97.CrossRefPubMed
23.
go back to reference Nashar K, Fried LF. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? Adv Chronic Kidney Dis. 2012;19(6):386–91.CrossRefPubMed Nashar K, Fried LF. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? Adv Chronic Kidney Dis. 2012;19(6):386–91.CrossRefPubMed
24.
go back to reference Filiopoulos V, Hadjiyannakos D, Vlassopoulos D. New insights into uric acid effects on the progression and prognosis of chronic kidney disease. Ren Fail. 2012;34(4):510–20.CrossRefPubMed Filiopoulos V, Hadjiyannakos D, Vlassopoulos D. New insights into uric acid effects on the progression and prognosis of chronic kidney disease. Ren Fail. 2012;34(4):510–20.CrossRefPubMed
25.
go back to reference Sharma P, Goodrich NP, Schaubel DE, Guidinger MK, Merion RM. Patient-specific prediction of ESRD after liver transplantation. J Am Soc Nephrol. 2013;24(12):2045–52.CrossRefPubMedPubMedCentral Sharma P, Goodrich NP, Schaubel DE, Guidinger MK, Merion RM. Patient-specific prediction of ESRD after liver transplantation. J Am Soc Nephrol. 2013;24(12):2045–52.CrossRefPubMedPubMedCentral
26.
go back to reference Gonwa TA, McBride MA, Anderson K, Mai ML, Wadei H, Ahsan N. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2006;6(11):2651–9.CrossRef Gonwa TA, McBride MA, Anderson K, Mai ML, Wadei H, Ahsan N. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2006;6(11):2651–9.CrossRef
27.
go back to reference Mok Y, Lee SJ, Kim MS, Cui W, Moon YM, Jee SH. Serum uric acid and chronic kidney disease: the Severance cohort study. Nephrol Dial Transplant. 2012;27(5):1831–5.CrossRefPubMed Mok Y, Lee SJ, Kim MS, Cui W, Moon YM, Jee SH. Serum uric acid and chronic kidney disease: the Severance cohort study. Nephrol Dial Transplant. 2012;27(5):1831–5.CrossRefPubMed
28.
go back to reference Nacak H, van Diepen M, Qureshi AR, Carrero JJ, Stijnen T, Dekker FW, Evans M: Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease. Nephrol Dial Transplant. 2015;30(12):2039-45. Nacak H, van Diepen M, Qureshi AR, Carrero JJ, Stijnen T, Dekker FW, Evans M: Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease. Nephrol Dial Transplant. 2015;30(12):2039-45.
29.
go back to reference Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11(5):974–9.PubMed Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11(5):974–9.PubMed
30.
go back to reference Laine J, Holmberg C. Tubular effects of cyclosporine in pediatric renal transplant recipients. Transplant Proc. 1996;28(4):2104–6.PubMed Laine J, Holmberg C. Tubular effects of cyclosporine in pediatric renal transplant recipients. Transplant Proc. 1996;28(4):2104–6.PubMed
31.
go back to reference Hansen JM, Fogh-Andersen N, Leyssac PP, Strandgaard S. Glomerular and tubular function in renal transplant patients treated with and without ciclosporin A. Nephron. 1998;80(4):450–7.CrossRefPubMed Hansen JM, Fogh-Andersen N, Leyssac PP, Strandgaard S. Glomerular and tubular function in renal transplant patients treated with and without ciclosporin A. Nephron. 1998;80(4):450–7.CrossRefPubMed
32.
go back to reference Li S, Sanna S, Maschio A, Busonero F, Usala G, Mulas A, Lai S, Dei M, Orru M, Albai G, et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet. 2007;3(11):e194.CrossRefPubMedPubMedCentral Li S, Sanna S, Maschio A, Busonero F, Usala G, Mulas A, Lai S, Dei M, Orru M, Albai G, et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet. 2007;3(11):e194.CrossRefPubMedPubMedCentral
33.
go back to reference Matsuo H, Nakayama A, Sakiyama M, Chiba T, Shimizu S, Kawamura Y, Nakashima H, Nakamura T, Takada Y, Oikawa Y, et al. ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload. Sci Rep. 2014;4:3755.PubMedPubMedCentral Matsuo H, Nakayama A, Sakiyama M, Chiba T, Shimizu S, Kawamura Y, Nakashima H, Nakamura T, Takada Y, Oikawa Y, et al. ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload. Sci Rep. 2014;4:3755.PubMedPubMedCentral
34.
go back to reference Yang B, Mo Z, Wu C, Yang H, Yang X, He Y, Gui L, Zhou L, Guo H, Zhang X, et al. A genome-wide association study identifies common variants influencing serum uric acid concentrations in a Chinese population. BMC Med Genet. 2014;7:10. Yang B, Mo Z, Wu C, Yang H, Yang X, He Y, Gui L, Zhou L, Guo H, Zhang X, et al. A genome-wide association study identifies common variants influencing serum uric acid concentrations in a Chinese population. BMC Med Genet. 2014;7:10.
Metadata
Title
Hyperuricemia after orthotopic liver transplantation: divergent associations with progression of renal disease, incident end-stage renal disease, and mortality
Authors
Joseph C. Longenecker
Sana Waheed
Ghassan Bandak
Christine A. Murakami
Blaithin A. McMahon
Allan C. Gelber
Mohamed G. Atta
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2017
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-017-0518-5

Other articles of this Issue 1/2017

BMC Nephrology 1/2017 Go to the issue